Portland-based healthcare startup Reperio Health has secured $14 million in fresh funding, enabling the company to expand its innovative in-home health screening services across the United States. The latest investment round, led by Caduceus Capital Partners, brings Reperio’s total funding to $32 million since its founding in 2020.
The company’s expansion plans include extending its recently introduced telehealth services beyond its initial markets of Oregon and Washington to serve patients nationwide. Reperio’s comprehensive health screening solution provides customers with testing kits containing various medical devices for at-home use.
These kits include equipment for measuring vital health metrics such as blood pressure and heart rate, along with tools for determining body mass index through weight and measurements. Additionally, the kits feature blood testing capabilities that deliver immediate results for key health indicators including cholesterol, triglycerides, lipids, and glucose levels.
The company’s technology platform incorporates a user-friendly mobile application that guides individuals through the testing process. Results are automatically transmitted from the testing devices to the platform via Bluetooth connectivity. Following the completion of home testing, users can now engage with healthcare providers through Reperio’s telehealth services to discuss their results and receive professional guidance.
In an environmentally conscious approach, the testing devices are returned to Reperio after use, where they undergo sterilization before being redistributed to other users. The company serves a diverse customer base, including employers, health insurance providers, medical practitioners, and individual consumers.
The leadership behind Reperio Health brings significant experience in healthcare innovation. CEO Travis Rush and Chief Technology Officer Matt Wallington, who co-founded the company, previously collaborated at Sightbox, another healthcare startup. Sightbox, which Rush founded, offered subscription-based services for eye examinations and contact lens provisions. The company’s success led to its acquisition by Johnson & Johnson in 2017.
Reperio’s home testing model represents a significant shift in how health screenings can be conducted, making preventive health measures more accessible and convenient for users. The combination of physical testing capabilities with telehealth services creates a comprehensive healthcare solution that aligns with modern consumer preferences for convenient, at-home services.
The platform’s technology integration, featuring Bluetooth-connected devices and immediate result reporting, streamlines the health screening process while maintaining accuracy and reliability. This approach eliminates common barriers to regular health screening, such as scheduling difficulties and travel requirements.
The ability to discuss results immediately with healthcare providers through telehealth services adds a crucial layer of professional medical support to the home testing experience. This integration of services ensures that users not only receive their health metrics but also understand their implications and can take appropriate action based on professional medical advice.
The substantial investment in Reperio Health suggests strong market confidence in the company’s business model and growth potential. As healthcare delivery continues to evolve, particularly in the wake of increased demand for remote health services, Reperio’s expansion positions the company to meet growing market needs for accessible health screening solutions.
The funding will support Reperio’s national expansion efforts, potentially making their services available to a significantly larger population across the United States. This growth represents a meaningful step toward improving access to preventive health screening services while maintaining the convenience and privacy of at-home testing.